Inspire Medical Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 01, 2022 at 04:11 pm EDT
Share
Inspire Medical Systems, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 109.19 million compared to USD 61.69 million a year ago. Net loss was USD 16.85 million compared to USD 10.35 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 0.38 a year ago. Diluted loss per share from continuing operations was USD 0.6 compared to USD 0.38 a year ago.
For the nine months, sales was USD 269.96 million compared to USD 155 million a year ago. Net loss was USD 48.03 million compared to USD 39.65 million a year ago. Basic loss per share from continuing operations was USD 1.73 compared to USD 1.46 a year ago. Diluted loss per share from continuing operations was USD 1.73 compared to USD 1.46 a year ago.
Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire system is the FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The Company has developed a novel, closed-loop solution that continuously monitors a patientâs breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sell its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ENT physicians and sleep centers.
INSPIRE MEDICAL SYSTEMS, INC. 
